In vivo reprogramming drives Kras-induced cancer development by Shibata, Hirofumi et al.
Title In vivo reprogramming drives Kras-induced cancerdevelopment
Author(s)
Shibata, Hirofumi; Komura, Shingo; Yamada, Yosuke;
Sankoda, Nao; Tanaka, Akito; Ukai, Tomoyo; Kabata, Mio;
Sakurai, Satoko; Kuze, Bunya; Woltjen, Knut; Haga, Hironori;
Ito, Yatsuji; Kawaguchi, Yoshiya; Yamamoto, Takuya;
Yamada, Yasuhiro




© The Author(s) 2018. This article is licensed under a Creative
Commons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in any
medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The
images or other third party material in this article are included
in the article’s Creative Commons license, unless indicated
otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your
intended use is not permitted by statutory regulation or exceeds
the permitted use, you will need to obtain permission directly






In vivo reprogramming drives Kras-induced cancer
development
Hirofumi Shibata1,2, Shingo Komura1, Yosuke Yamada1,3, Nao Sankoda4, Akito Tanaka1, Tomoyo Ukai1,
Mio Kabata1, Satoko Sakurai1, Bunya Kuze2, Knut Woltjen 1,5, Hironori Haga3, Yatsuji Ito2,
Yoshiya Kawaguchi4, Takuya Yamamoto 1,6 & Yasuhiro Yamada1,6,7
The faithful shutdown of the somatic program occurs in the early stage of reprogramming.
Here, we examined the effect of in vivo reprogramming on Kras-induced cancer development.
We show that the transient expression of reprogramming factors (1–3 days) in pancreatic
acinar cells results in the transient repression of acinar cell enhancers, which are similarly
observed in pancreatitis. We next demonstrate that Kras and p53 mutations are insufﬁcient to
induce ERK signaling in the pancreas. Notably, the transient expression of reprogramming
factors in Kras mutant mice is sufﬁcient to induce the robust and persistent activation of ERK
signaling in acinar cells and rapid formation of pancreatic ductal adenocarcinoma. In contrast,
the forced expression of acinar cell-related transcription factors inhibits the pancreatitis-
induced activation of ERK signaling and development of precancerous lesions in Kras-mutated
acinar cells. These results underscore a crucial role of dedifferentiation-associated epigenetic
regulations in the initiation of pancreatic cancers.
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Induced pluripotent stem cells (iPSCs) can be established fromsomatic cells by the transient expression of pluripotency-related transcription factors (TFs)1. Given that epigenetic
regulation plays a central role in cell fate determination and
maintenance, this technology allows for the reorganization of
epigenetic regulation from the differentiated somatic cell state into
the pluripotent state without affecting genetic information2–4.
Recent studies revealed the stepwise epigenetic changes during
iPSC derivation5,6. In early-stage reprogramming, the faithful
shutdown of the somatic program occurs through the silencing of
somatic cell-speciﬁc enhancers, which is associated with a loss of
original cell identity. Upon prolonged expression of the repro-
gramming factors, gradual activation of the pluripotency-related
transcriptional network is observed in late-stage reprogramming.
Notably, such events in cellular reprogramming are similarly
observed in cancer development. Cancer cells often lack terminal
differentiation ability, suggesting that repression of the somatic
cell program is involved in cancer development. In contrast,
poorly differentiated cancers that lose most differentiation fea-
tures sometimes exhibit an activation of pluripotency-related
genes such as targets of Nanog, Oct3/4, and Sox2 (ref. 7). More-
over, poorly differentiated cancers with pluripotency-related gene
expressions are associated with high malignancy, especially in the
mammary glands7. Collectively, these ﬁndings suggest that some
aspects of cellular reprogramming are associated with cancer
development.
Indeed, our previous study demonstrated that premature ter-
mination of in vivo reprogramming leads to kidney cancer
development through altered epigenetic regulation8. Consistent
with the partial reprogramming state, these cancer cells lose
kidney cell-speciﬁc molecular signatures while they partially
acquire the trait of embryonic stem cells (ESCs) including self-
renewing capacity. Notably, these cancers resemble Wilms’
tumor, which is the most common childhood kidney cancer.
Furthermore, these cancer cells were readily reprogrammable into
iPSCs that are capable of differentiating into non-cancerous
kidney cells8. These results raised the possibility that
reprogramming-associated epigenetic regulation has a signiﬁcant
impact on childhood cancer development, which is also in
agreement with recent observations that childhood cancers har-
bor relatively few genetic mutations. However, the functional
signiﬁcance of epigenetic regulation related to cellular repro-
gramming remains largely unclear in adult cancer development.
Pancreatic cancer is one of the most common causes of cancer
mortalities in adults in developed countries. The median survival
period is less than 6 months and the 5-year survival rate is 3–5%
9,10. The most common type of pancreatic cancer is pancreatic
ductal adenocarcinoma (PDAC). PDAC is one of the well-
characterized cancers for multistep cancer progression models
that have “Big 4” mutations (mutations in KRAS, CDKN2A,
TP53, and SMAD4)11,12. Histologically, PDAC is thought to arise
from a spectrum of preneoplastic lesions with ductal morphology
that are designated as pancreatic intraepithelial neoplasia (PanIN)
13. Since early PanIN lesions harbor mutations or ampliﬁcation of
the KRAS at high frequency (over 90%), it has been proposed that
KRAS mutation is responsible for PanIN formation and thus is an
initial event during pancreatic cancer development14,15. In con-
trast to premalignant lesions, PDAC often harbors additional
mutations such as a loss of CDKN2A and inactivating mutations
at TP53 and SMAD411. Together, current consensus holds that
pancreatic cancer arises through a stepwise progression with
characteristic genetic mutations for each histologically distin-
guishable stage.
In the present study, based on the shared properties between
cellular reprogramming and cancer development, we examined
the effect of in vivo reprogramming in the development of Kras-
induced cancer. We show that reprogramming-mediated repres-
sion of somatic cell enhancers, which is associated with early stage
of reprogramming, in conjunction with Kras mutation results in
rapid development of PDAC. We also show that partial acquisi-
tion of the ESC signature, which occurs later stage of repro-
gramming, causes the development of cancers that resemble
human α-fetoprotein (AFP)-producing cancer. These results
highlight the crucial role of reprogramming-related epigenetic
regulation in Kras-induced cancer in vivo.
Results
Kras and p53mutations are insufﬁcient for ERK activation. We
ﬁrst generated Pdx1-ires-Cre knocked-in ESCs by homologous
recombination (Fig. 1a and Supplementary Fig. 1A), and then
Pdx1-ires-Cre knocked-in mice to induce pancreas-speciﬁc
Cre-LoxP recombination. Lineage tracing analysis of Pdx1-ires-
Cre mouse using Rosa26 LacZ reporter allele16 conﬁrmed that the
Cre-LoxP recombination occurs in almost all pancreatic cells
(Supplementary Fig. 1B, C), which was consistent with a previous
report using transgenic mice expressing Pdx1-Cre17. Similarly, we
knocked-in LoxP-Stop-loxP (LSL)-HA tag-KrasG12D allele into
endogenous Kras locus in ESCs (Supplementary Fig. 1D) and
generated knocked-in mice. We then generated LSL-HA tag-
KrasG12D and Pdx1-ires-Cre (hereafter HA-KC) compound mice
to examine the expression of KrasG12D oncoprotein (Fig. 1a). HA
immunostaining exhibited membranous expression of KrasG12D
oncoprotein in the pancreatic cells of HA-KC mice at 6 weeks of
age (Fig. 1b). However, despite the expression of KrasG12D
oncoprotein, most pancreatic cells were histologically normal
(Fig. 1b) except for the focal formation of early PanIN, indicating
that Kras mutation alone cannot transform pancreatic acinar
cells.
To further investigate the effect of oncogenic mutations on the
ERK signaling pathway and aberrant proliferation, we next
generated LSL-KrasG12D, Pdx1-ires-Cre (KC) mice and LSL-
KrasG12D, LSL-p53R172H, Pdx1-ires-Cre (KPC) compound mice
(Fig. 1c) using well-established Kras and p53 mutant alleles18,19.
In accordance with the results in HA-KC mice, most pancreatic
cells exhibited recombination in both KrasG12D and p53R172H
alleles in KPC mouse (Fig. 1d, Supplementary Fig. 9). However,
the majority of pancreatic cells were histologically normal in both
KC and KPC mice at 6 weeks of age, except for the spotted
formation of early PanIN and the dysplastic area (Fig. 1e).
Although PDAC development was observed in KPC mice at
8 weeks of age, the affected area was still limited, and most
pancreatic cells remained histologically normal (Fig. 1e). Con-
sistently, pERK immunostaining showed positive staining only in
PanIN and PDAC lesions, while the majority of pancreatic cells
were negative for pERK (Fig. 1e), demonstrating that compound
mutations of Kras and p53 are insufﬁcient for robust activation of
the ERK pathway. Similarly, the majority of pancreatic cells in
KPC mice were negative for Ki67, a cell proliferation marker
(Fig. 1e), which indicates that compound mutations of Kras and
p53 gene are insufﬁcient for inducing the abnormal proliferation
of pancreatic cells. These results suggest that aberrations beyond
Kras and p53 mutations are required for PDAC development.
Reversible ductal metaplasia by in vivo reprogramming. In
order to investigate the inﬂuence of in vivo reprogramming in the
pancreas, we next generated mice in which reprogramming fac-
tors can be induced speciﬁcally in the pancreas upon doxycycline
(Dox) treatment. We established mice harboring Pdx1-ires-Cre,
Rosa LSL-rtTA3, and Col1a1::tetO-Oct3/4, Sox2, Klf4, c-Myc-ires-
mCherry (hereafter C-OSKM) (Fig. 2a). After Dox treatment, we
conﬁrmed mCherry ﬂuorescence in the pancreas of these mice
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Fig. 1 Kras/p53 compound mutations are insufﬁcient for PDAC development. a A schematic illustration of the genetic construct to activate HA-KrasG12D in
the pancreas. b Representative histology and immunostaining for HA-KrasG12D. Scale bars, 50 μm. c Genetic strategy to study the inﬂuence of somatic
activation of Kras and p53mutations in the pancreas. d Southern blotting of LSL-KrasG12D and LSL-p53R172H allele. ESCs containing Pdx1 ires-Cre, LSL-KrasG12D
and LSL-p53R172H alleles were used as control. Note that majority of two LoxP alleles are converted into one LoxP allele in the pancreas of KPC mouse (Cont
control, Panc pancreas). e Immunostaining for pERK and Ki67 in the pancreas of 6-week-old wild-type mice, KC mice, and KPC mice. KPC mice at 8 weeks
of age showed a focal PDAC area with pERK staining (bottom). Scale bars: HE and pERK (low magniﬁcation) staining, 200 μm; pERK (high magniﬁcation)
staining, 50 μm; and Ki67 staining, 100 μm
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(Supplementary Fig. 2A). We also performed histological analysis
of 4-week-old mice given Dox for 3 days (Fig. 2b).
It has been proposed that the transition of acinar cells into a
duct-like state (acinar to ductal metaplasia (ADM)) is an early
event of pancreatic cancer development20–22. Notably, Dox-
treated mice often exhibited dilatation of the acinar glands and
expression of CK19, a ductal marker (Fig. 2c). CK19 expression
was sometimes observed in amylase-expressing cells (Fig. 2c),
suggesting that ADM occurs by the short induction of
reprogramming factors. Consistent with this notion, Oct3/4
expression was observed in newly formed ductal cells (Fig. 2d).
Notably, after 1 week of Dox withdrawal, the histology of the
pancreas was almost normal, and CK19-expressing ADM lesions
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epigenetic memory of acinar cells. Taken together, these results
show that the 3-day expression of reprogramming factors causes
reversible ADM phenotype.
A recent study demonstrated that continuous Klf4 over-
expression induces ADM23. To further investigate whether
cellular reprogramming is indeed related to ADM formation,
we next examined the effect of another reprogramming cocktail
that lacks Klf4. For this purpose, we established ESCs with Dox-
inducible polycistronic cassette containing Sall4, Nanog, Esrrb,
and Lin28 (hereafter SNEL), which was reported as an alternative
reprogramming factor cocktail, using the KH2-ESC system
(Fig. 2g)24,25. To investigate the effect of SNEL expressions on
reprogramming, mouse embryonic ﬁbroblasts (MEFs) containing
Dox-inducible SNEL alleles were established from E13.5 embryos.
After 2 weeks of Dox exposure to SNEL-MEFs, iPSC-like colonies
were observed (Supplementary Fig. 2B, C). Although these iPSC-
like colonies could not be expanded, they exhibited increased
alkaline phosphatase activity (Supplementary Fig. 2D), reﬂecting
the partial reprogramming state. We then examined the in vivo
effect of SNEL expression in the pancreas. After Dox treatment,
SNEL-inducible chimeric mice exhibited mCherry ﬂuorescence in
various organs, including the pancreas (Supplementary
Fig. 2E, F). Notably, Dox treatment longer than 2 weeks resulted
in the formation of ADM lesions in the pancreas (Fig. 2h, i).
Consistently, CK19-positive regions often co-expressed amylase
(Fig. 2j), indicating that ADM was similarly induced by SNEL
expression. Moreover, the ADM lesions were hardly detectable at
1 week after Dox withdrawal, suggesting that the SNEL-induced
ADM phonotype is reversible (Supplementary Fig. 2G). Collec-
tively, these results indicate that the transient expression of
reprogramming factor cocktails induces reversible ADM
phenotype.
In vivo reprogramming represses acinar cell enhancers. To
investigate the molecular basis of reprogramming-mediated ADM
formation, we ﬁrst examined transcriptional changes of the
pancreas during in vivo reprogramming. The pancreas of C-
OSKM mice given Dox for 3 days was analyzed for global gene
expressions by microarray. In accordance with histological evi-
dence of ADM formation, the expression of acinar cell-related
TFs such as Ptf1a and Mist1 (Bhlha15) was reduced, while the
expression of CK19 (Krt19), a ductal cell-speciﬁc gene, was
markedly increased (Fig. 3a). In addition, ADM-related genes
such as Muc5ac, Tff1, and Plac8 were similarly upregulated
(Fig. 3a)26,27. To examine the initial transcriptional response after
OSKM induction, we next treated C-OSKM mice with Dox via i.p.
injection and examined gene expressions after 24 h. Notably,
marked repression of Ptf1a and Mist1 was already detectable at
24 h after Dox treatment (Fig. 3b). Conversely, CK19 and ADM-
related genes were upregulated in these samples (Fig. 3b),
suggesting that the silencing of acinar cell-related genes is coupled
with the induction of ADM-related genes.
Previous studies demonstrated that silencing of the somatic
cell-speciﬁc enhancers is an initial epigenetic event during
reprogramming5,6. We next examined the effect of reprogram-
ming factor expressions on the enhancers of pancreatic cells.
ChIP-seq analysis for H3K27ac was performed using the
pancreas of C-OSKM mice given Dox for 3 days. A perfusion
ﬁxation protocol was employed for cross-linking chromatin
in vivo. Consistent with reduced expressions, H3K27ac deposi-
tion was signiﬁcantly reduced at the enhancers of several acinar
cell-related genes including Ptf1a, Mist1 (Bhlha15), Nr5a2, and
Cpa1 (Fig. 3c and Supplementary Fig. 3A) after Dox treatment,
but it was not altered at the control Actb gene (Supplementary
Fig. 3B). In contrast, H3K27ac deposition was not increased in
upregulated genes, such as CK19 or in ADM-related genes
(Supplementary Fig. 3C), which supports the notion that the
repression of acinar cell enhancers is an initial epigenetic
regulation step after reprogramming factor expression. Simi-
larly, Sox9, a key TF in ductal cells22,28, did not exhibit an
enrichment of H3K27ac deposition (Supplementary Fig. 3C).
Furthermore, genome-wide analysis revealed that enhancers
including super enhancers (SEs)29,30 are signiﬁcantly repressed
after Dox treatment for 3 days (Fig. 3d and Supplementary
Fig. 3D, E). Consistently, the number of enhancers and SEs were
substantially decreased by Dox treatment for 3 days (Fig. 3d and
Supplementary Fig. 3E). Moreover, the expressions of genes
linked with Dox OFF-speciﬁc SEs were decreased by Dox
treatment, while genes linked with common-SEs or Dox ON-
speciﬁc SEs were not repressed (Fig. 3e). Ptf1a promoter and
enhancer remained unmethylated in the pancreas after 3 days of
Dox treatment (Supplementary Fig. 3F), indicating that DNA
methylation was not involved in the Ptf1a repression. Notably,
the Dox-induced reduction of H3K27ac deposition was not
observed at 2 weeks after Dox withdrawal, indicating the
repression of SEs is reversible (Fig. 3d). Collectively, these
results suggest that reprogramming factor expression causes
transient epigenetic repression of acinar cell enhancers and loss
of acinar cell identity, which lead to ADM formation. To further
connect the loss of acinar cell enhancer with ADM formation,
we induced acinar-cell-related TFs (Mist1 or Ptf1a) together
with OSKM in the pancreas (Supplementary Fig. 4A–C).
Notably, the co-expression of Ptf1a or Mist1 with OSKM
attenuated the OSKM-induced expression of CK19 and ADM
formation (Fig. 3f and Supplementary Fig. 4D). Together, these
results suggest that the silencing of acinar cell program causes
the induction of ADM.
Finally, to connect OSKM-induced ADM formation with
pathological conditions, we examined the effect of caerulein
treatment, which is well-established pancreatitis stimuli and
induces transient ADM formation, on pancreatic SEs. We
Fig. 2 Transient expression of reprogramming factors induces reversible acinar to ductal metaplasia. a A schematic illustration of the genetic construct of
Pdx1 ires-Cre, Rosa LSL-rtTA3, Col1a1::tetO-OSKM-ires-mCherry (C-OSKM) mice. b Experimental protocol for Dox treatment in C-OSKM mice. c
Immunoﬂuorescent images for Amylase and CK19 in the pancreas of C-OSKM mice. CK19 expression is observed in the acinar area of C-OSKM mice after
Dox treatment for 3 days. Scale bars, 50 μm. d Immunoﬂuorescent images for Oct3/4 and CK19 in the pancreas of C-OSKM mice. Transgenic Oct3/4
expression is coincident with the CK19-positive lesions. Scale bars, 50 μm. e Reversible ductal metaplasia by the transient expression of reprogramming
factors. CK19 staining is hardly detected in the acinar area after Dox withdrawal for 1 week. Scale bars, 50 μm. f Quantiﬁcation of the CK19-positive area in
the pancreas of C-OSKMmice. A box-and-whisker plot of the CK19-positive area. Solid lines in each box indicate the median. Bottom and top of the box are
lower and upper quartiles, respectively. Whiskers extend to ±1.5 interquartile range (IQR). Numbers in parentheses indicate the number of mice examined.
***p < 0.001, Mann–Whiteney U-test. n.s. not signiﬁcant. g A schematic illustration of the genetic constructs of Rosa M2-rtTA, Col1a1::tetO-SNEL-ires-
mCherry (KH2-SNEL) mice. Polycistronic cassette was used for SNEL induction. h Experimental protocol for Dox treatment in KH2-SNEL chimeric mice. i
CK19 expression in Dox-treated KH2-SNEL chimeric mice. ADM lesions are observed after SNEL expression for 2 weeks. Scale bar, 50 μm. j
Immunoﬂuorescent images for Amylase and CK19 staining in KH2-SNEL chimeric mice. CK19 expression is observed in the amylase-positive acinar area
after SNEL expression. Scale bars, 50 μm
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performed intraperitoneal injection of caerulein eight times for
2 days (2 μg/injection every consecutive hour for 7 h) and
performed ChIP-seq analysis for H3K27ac after 24 h at Day 3.
Histological analysis revealed that OSKM-expressing pancreatic
lesions phenocopies caerulein-induced ADM lesions
(Supplementary Fig. 4E). Consistent with previous studies, we
conﬁrmed that the caerulein treatment causes reduced expression
of acinar cell-related genes such as Ptf1a and Mist1 (Supplemen-
tary Fig. 4F). Of particular note, enhancers that are altered by
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(Fig. 3g and Supplementary Fig. 4G). Taken together, our results
suggest that inﬂammatory stimuli induce ADM formation
through repression of somatic enhancers.
In vivo reprogramming activates ERK in Kras mutant pan-
creas. To elucidate the inﬂuence of the loss of acinar cell identity
on Kras-mutated pancreatic cells, we next established ESCs
containing LSL-KrasG12D, Pdx1-ires-Cre, Rosa LSL-rtTA3, and
Col1a1::tetO-OSKM-ires-mCherry (hereafter KC-OSKM) and
generated chimeric mice to induce Kras mutation and repro-
gramming factors simultaneously in the pancreas (Fig. 4a). The
experimental protocol of Dox treatment for OSKM induction is
shown in Fig. 4b. Consistent with our ﬁndings that OSKM
expression induces ADM, increased expression of CK19 was
observed in both C-OSKM mice and KC-OSKM mice (Fig. 4c).
Notably, pERK was strongly induced in CK19-positive area of
KC-OSKM mice whereas such induction was modest in C-OSKM
mice (Fig. 4c), suggesting that Kras mutation cooperatively acti-
vates the ERK pathway in conjunction with reprogramming
factor expression (Fig. 4c). In sharp contrast to reversible ductal
metaplasia in C-OSKM mice, CK19-expressing ducts were
observed even at 1 week after Dox withdrawal in KC-OSKM mice
(Fig. 4d), suggesting that the ADM phenotype is sustained in the
presence of Kras mutation. Consistently, increased expression of
pERK was sustained in the ductal area at 1 week after Dox
withdrawal in KC-OSKM mice (Fig. 4e, f). Furthermore, ductal
lesions were histologically displayed PanIN/PDAC (Fig. 4d, e,
Supplementary Fig. 5A). The affected lesions sometimes displayed
positive staining for Alcian blue, a PanIN marker, and often
exhibited widespread Sirius red staining, which showed that
massive ﬁbrosis simultaneously occurs in PanIN/PDAC lesions
within 10 days of Dox exposure (Fig. 4e, f, Supplementary
Fig. 5B).
Previous studies have demonstrated that increased expression
of endogenous EGFR activates the MAPK pathway in human and
mouse PanIN/PDAC area31,32. To unveil the molecular mechan-
ism for persistent activation of the ERK signaling pathway in KC-
OSKM mice, we examined EGFR expression in Dox-treated
C-OSKM and KC-OSKM mice. Although Dox treatment for
3 days increased EGFR expression in both C-OSKM and KC-
OSKM mice, the increased EGFR levels were pronounced in
KC-OSKM mice, while only modest expression was observed in
C-OSKMmice (Fig. 4g and Supplementary Fig. 5C). Furthermore,
the increased EGFR expression was sustained in KC-OSKM mice
even after Dox withdrawal, whereas C-OSKM mice showed
almost no EGFR staining (Fig. 4g and Supplementary
Fig. 5C, 5D), suggesting that Kras mutation is involved in robust
and continuous EGFR expression through positive feedback
regulation. Western blot conﬁrmed the sustained activation of the
ERK signaling pathway and increased EGFR expression in the
pancreas of KC-OSKM mice even after Dox withdrawal (Fig. 4h,
Supplementary Fig. 9). These results suggest that maintenance of
the acinar cell trait prevents ERK signaling activation in the
pancreas of Kras mutant mice.
p53 mutation accelerates Kras/OSKM-induced PDAC. An
inactivating mutation at the p53 gene was reported to promote
PDAC formation33,34. To investigate the effect of p53 mutation
on in vivo reprogramming-mediated development of pancreatic
lesions in Kras mutant background, we next generated chimeric
mice containing LSL-KrasG12D, LSL-p53R172H, Pdx1-ires-Cre,
Rosa LSL-rtTA3, and Col1a1::tetO-OSKM-ires-mCherry (hereafter
KPC-OSKM) (Fig. 5a). The time course of Dox treatment is
shown in Fig. 5b. Transient induction of OSKM in the pancreas of
KPC-OSKM mice signiﬁcantly increased the CK19- and
pERK-positive area, which persisted even after withdrawal of Dox
(Supplementary Fig. 5E, F) as similarly observed in KC-OSKM
mice. Notably, KPC-OSKM mice developed predominantly
PDAC within 10 days of OSKM induction, while KC-OSKM mice
developed mixed lesions containing both PanIN and PDAC
(Fig. 5c–e). Consistently, Dox-treated KPC-OSKM mice showed a
signiﬁcant reduction of PanIN-related Alcian blue-positive area
when compared with Dox-treated KC-OSKM mice (Supplemen-
tary Fig. 5G). Dox-treated KPC-OSKM mice died within
3 months, and some mice developed cancerous ascites (Supple-
mentary Fig. 5H). Moreover, cell lines established from pancreatic
tumors in Dox-treated KPC-OSKM mice were able to develop
secondary tumors in the subcutaneous tissue of nude mice
(Supplementary Fig. 5I), afﬁrming that they have cancer-
initiating properties. Together, these results demonstrate that
compound mutations of Kras and p53 in cooperation with
transient repression of acinar cell enhancers are sufﬁcient for the
rapid and widespread induction of PDAC.
We further examined mechanistic insights into the phenotypic
difference between KC-OSKM and KPC-OSKM mice after Dox
exposure. Given that escape from Kras-induced senescence is
associated with progression of PanIN and that the p21–p53
pathway is involved in oncogene-induced senescence35, we
particularly focused on the effect of p53R172H mutation on
cellular senescence. Consistent with the previous report that
found OSKM expression in vivo induces cellular senescence36,
widespread DNA damage response, which was measured by
γH2AX staining, as well as increased p21 expression were
detected after Dox treatment in C-OSKM mice (Supplementary
Fig. 5J). Consistently, an increased deposition of H3K27ac was
observed in Cdkn1a (p21) after Dox treatment for 3 days in C-
OSKM mice (Supplementary Fig. 5K). Notably, the induction of
γH2AX and p21 was indistinguishable among C-OSKM,
KC-OSKM, and KPC-OSKM mice (Supplementary Fig. 5J),
suggesting that oncogenic Kras mutation and p53 mutation
hardly affect the immediate senescence-associated response
against reprogramming factor expressions. After withdrawal of
Fig. 3 Repression of acinar cell enhancers by in vivo reprogramming. aMicroarray analysis in the pancreas of C-OSKM mice given Dox for 3 days. b A qRT-
PCR for acinar cell-related genes and ADM-related genes after Dox treatment for 24 h in the pancreas of C-OSKMmice. Data are presented as the mean of
technical triplicates. The mean expression level of wild-type samples was set to 1 for Amy, Mist1, Ptf1a, and CK19. For Tff1 and Muc5ac, the mean expression
level of Dox 24 h samples was set to 1. c ChIP-seq analysis for H3K27ac in the pancreas of C-OSKM mice. Note that H3K27ac deposition is substantially
reduced at acinar cell-related transcription factors (Ptf1a and Mist1). d Super enhancers (SEs) in the pancreas of C-OSKM mice. Note that Dox OFF-speciﬁc
SEs show signiﬁcant reduction in H3K27ac deposition in Dox ON pancreas. The number of SEs is decreased after Dox treatment for 3 days. e Dox OFF-
speciﬁc SE-related gene expressions are signiﬁcantly suppressed by OSKM induction. ***p < 0.001, Mann–Whiteney U-test. f Forced expression of an
acinar cell-related transcription factor (Ptf1a or Mist1) inhibits OSKM-induced ADM formation. EGFP expression represents the expression of either Ptf1a or
Mist1. Note that most EGFP-expressing cells are negative for CK19 while the control EGFP-expressing cells often costained with CK19. Scale bars, 50 μm.
The ratio of CK19-positive cells in EGFP-positive cells of 10 independent images are shown in a box-and-whisker plot. Solid lines in each box indicate the
median. Bottom and top of the box are lower and upper quartiles, respectively. Whiskers extend to ±1.5 interquartile range (IQR). ***p < 0.001,
Mann–Whiteney U-test. g Super enhancers (SEs) in caerulein-treated pancreas. Note that caerulein treatment causes reduction in H3K27ac deposition at
SEs that are repressed by OSKM induction
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Dox for 1 week, however, the p21- and γH2AX-positive area was
substantially reduced in proliferating lesions of both KC-OSKM
and KPC-OSKM mice (Supplementary Fig. 6A–C), suggesting
that escape from senescence occurs regardless of the p53 status.
Consistently, there was no signiﬁcant difference in the survival
rate between Dox-treated KC-OSKM mice and Dox-treated
KPC-OSKM mice (Supplementary Fig. 6D), suggesting that Kras
mutation alone together with transient repression of acinar cell
enhancers cause the escape from senescence and the rapid PDAC
development.
Taken together, our results demonstrate that the repression of
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subsequent cancer growth in Kras-mutated acinar cells of the
pancreas. Finally, we tried to maintain acinar cell enhancers by
expressing acinar cell-speciﬁc TFs (Ptf1a or Mist1) in caerulein-
treated KC mice, in which caerulein-induced inﬂammation
initiates ADM/PanIN formation and activates ERK signaling
(Fig. 5f and Supplementary Fig. 4E). Notably, forced expression of
either Ptf1a or Mist1, but not the control mCherry, strongly
inhibited PanIN formation (Fig. 5g and Supplementary Fig. 7A).
Consistently, pERK staining was signiﬁcantly reduced by the
expression of acinar cell-related TFs (Fig. 5h). These results
provide additional evidence that acinar cell enhancers safeguard
Kras-induced cancer initiation.
Undifferentiated cancer development by in vivo reprogramming.
It has been shown that the acquisition of the pluripotency-related
epigenetic landscape occurs at late-stage reprogramming5,6. We
next extended the duration of reprogramming factor expression
in KC-OSKM mice to examine the effect of late epigenetic reg-
ulation of reprogramming on cancer development.
KC-OSKM mice were given Dox for 1–2 weeks, followed by Dox
withdrawal for 1–2 weeks. In contrast to the PanIN/PDAC for-
mation in KC-OSKM mice given Dox for 3 days, prolonged
treatment of Dox caused the development of histologically
undifferentiated cancer with higher proliferative activity in the
pancreas of KC-OSKM mice (Fig. 6a). Notably, these cancers
exhibited the expression of pluripotency-related proteins, Sall4
and Lin28a, independently of OSKM transgene expressions
(Fig. 6a).
We found that KC-OSKM mice given Dox for 1–2 weeks often
developed undifferentiated cancers in the stomach (Fig. 6b and
Supplementary Table 1), which is consistent with the observation
that Cre-LoxP recombination also occurs in the pyloric glands of
the stomach with Pdx1-ires-Cre allele (Supplementary Fig. 1B, C).
These gastric cancers similarly exhibited the expression of Sall4
and Lin28a (Fig. 6c). In agreement with the acquisition of
pluripotency-related epigenetic regulation, partial activation of
ESC-Core and ESC-Myc modules was observed in gastric cancers
in KC-OSKM mice (Supplementary Fig. 8A). C-OSKM mice
treated with Dox for 1–2 weeks also developed undifferentiated
cancer in the stomach (Supplementary Fig. 8B, C), albeit at lower
frequency than KC-OSKM mice (p < 0.01, Fisher’s exact test,
Supplementary Table 1), suggesting that the Kras mutation
promotes but is not essential for the development of undiffer-
entiated cancers.
In vivo reprogramming induces AFP-producing cancers.
Human AFP-producing cancers predominantly arise in the sto-
mach and display poorly differentiated histology and show dismal
prognosis37,38. Notably, we observed focal expression of Afp in
gastric cancers in KC-OSKM mice given Dox for 1–2 weeks
(Fig. 6c, d), which raised the possibility that the acquisition of
pluripotency-related epigenetic regulation is associated with the
development of human AFP-producing cancers. Therefore, we
next investigated the expression of pluripotency-related proteins
in human AFP-producing gastric cancers. Twenty-ﬁve gastric
cancers that were diagnosed as AFP-producing gastric cancers,
were examined for the expression of SALL4, LIN28A, and
LIN28B by immunostaining. Notably, as observed in gastric
cancers in KC-OSKM mice, SALL4, LIN28A, and LIN28B were
frequently co-expressed in human AFP-producing gastric cancers
(Fig. 6e, f and Supplementary Table 2), suggesting that these
cancers exhibit activation of the pluripotency-related regulatory
network.
Finally, we re-examined the microarray data previously used to
investigate 200 cases of human gastric cancers39. We found that
AFP, LIN28B, and SALL4 were overexpressed in seven, eight, and
nine cases of the 200 human gastric cancers, respectively.
Consistent with the frequent co-expression of pluripotency-
related proteins in human AFP-producing gastric cancers, partial
activation of ESC-Core and ESC-Myc modules was observed in
AFP-, LIN28B-, and SALL4-expressing human gastric cancers
(Fig. 6g and Supplementary Fig. 8D), while such activations were
not obvious in ERBB2-highly expressed gastric cancers (n= 12)
(Supplementary Fig. 8D), which recapitulated our observations of
reprogramming-induced gastric cancers in KC-OSKM mice.
Discussion
Cancer is believed to arise through an accumulation of genetic
mutations40,41. Indeed, genome-wide sequencing analyses have
revealed a number of driver mutations in multiple cancer types.
The functional signiﬁcance of such driver mutations has been
demonstrated by reverse genetic approaches where rodents in
which these mutations were introduced develop the same types of
cancer observed in human patients. However, the genetically
engineered cancer models always exhibit a substantial latency
period for cancer development, indicating that additional events
are required for the development of full-blown cancer. Therefore,
which sets of genetic mutations are sufﬁcient for cancer devel-
opment remains unclear in most cancers. Indeed, in the present
study we show that most pancreatic cells with compound
mutations at Kras and p53 display no obvious activation of the
ERK signaling pathway and exhibit normal histology at 6 weeks
of age, which is consistent with previous ﬁndings that oncogenic
KRAS mutations are detectable in human disease-free pancreas42.
Notably, we demonstrate that short, transient expression of
reprogramming factors in Kras mutant mice at 4 weeks of age
results in persistent ERK activation and widespread PDAC
development within 10 days, indicating that cellular reprogram-
ming is sufﬁcient for the initiation of cancer growth in pancreatic
cells with Kras mutation.
Alteration of the epigenetic modiﬁcations is one of the most
common aberrations detected in human cancers43–45. Decades of
studies have demonstrated that epigenetic regulation plays a
signiﬁcant role in cancer development both in vitro and in vivo.
Fig. 4 Transient expression of OSKM causes persistent activation of ERK signaling and PDAC/PanIN development in the Kras-mutated pancreas. a A
schematic illustration of the genetic construct of Pdx1 ires-Cre, LSL-KrasG12D, Rosa LSL-rtTA3, Col1a1::tetO-OSKM-ires-mCherry (KC-OSKM) mice to induce
pancreas-speciﬁc Kras mutation and in vivo reprogramming. b Experimental protocol for Dox treatment in KC-OSKM chimeric mice. c Immunoﬂuorescent
images for CK19 and pERK staining. Note that strong pERK staining is detectable in ADM lesions of KC-OSKM mice. Scale bars, 50 μm. d CK19
immunostaining of the pancreas in KC-OSKM chimeric mice. CK19-expressing cells are observed even after Dox withdrawal for 1 week. Scale bars, 100 μm.
e Representative images for HE, pERK, Alcian blue, and Sirius red staining in the pancreas of KC-OSKM chimeric mice. Scale bars, 100 μm. f Quantiﬁcation
of CK19-, pERK-, Alcian blue-, and Sirius red-positive areas in the pancreas of KC-OSKM chimeric mice. A box-and-whisker plot of the positive area. Solid
lines in each box indicate the median. Bottom and top of the box are lower and upper quartiles, respectively. Whiskers extend to ±1.5 interquartile range
(IQR). Numbers in parentheses indicate the number of mice examined. **p < 0.01, ***p < 0.001, Mann–Whiteney U-test. n.s. not signiﬁcant. g EGFR
immunostaining in the pancreas of KC-OSKM chimeric mice. Note that increased EGFR expression is induced by Dox treatment and sustained after Dox
withdrawal. Insets represent a higher magniﬁcation. Scale bars, 50 μm. h Western blot analysis for pERK, ERK, and EGFR of the pancreas. Increased and
sustained pERK and EGFR expression are observed in KC-OSKM mice
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However, recent sequencing analysis identiﬁed that most cancer
types harbor mutations at epigenetic modiﬁer genes at varying
frequencies, which has raised the possibility that genetic
abnormalities are the primary cause of the dysfunction or dys-
regulation of epigenetic modiﬁers that result in secondary
alterations in the cancer epigenome. Therefore, direct evidence of
bona ﬁde epigenetic alterations that drive cancer development is
still limited, especially in vivo.
iPSC derivation is mediated through epigenetic reorganization
without affecting genomic information. In the initial stage of
d
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reprogramming in vitro, reprogramming factors repress somatic
enhancers, which causes the repression of cell-type speciﬁc gene
expressions6. Consistently, the gradual repression of somatic cell-
speciﬁc gene expressions is similarly observed during in vivo
reprogramming8. Notably, the early reprogramming process
in vivo is reversible up to 7 days, which reﬂects epigenetic
memory of the cells at early-stage reprogramming8,46. In the
present study, we show that in vivo reprogramming primarily
represses acinar cell enhancers and induces remarkable down-
regulation of acinar cell-related genes such as Ptf1a and Mist1,
suggesting that in vivo reprogramming induces the loss of acinar
identity. The fact that this loss is reversible further supports the
notion that the process is an epigenetic event. Together, the rapid
and widespread development of PDAC by 3-day expression of
reprogramming factors provide in vivo evidence that transient
alteration of epigenetic regulation plays a critical role on cancer
initiation. Our results also highlight the signiﬁcance of
dedifferentiation-related epigenetic regulation in cancer initiation,
which may provide mechanistic insight into how dedifferentia-
tion is involved in cancer development.
Previous studies using genetically engineered mouse models
show that adult ductal cells are refractory to Kras mutation-
mediated oncogenic transformation. In contrast, adult acinar cells
are competent to give rise to PDAC in the presence of Kras
mutation in which ADM plays a role as an initiating event20–22.
Although ADM is associated with the initiation of Kras-mediated
abnormal cell growth, the cause of ADM formation remains to be
fully understood. Here we demonstrate that the repression of
acinar cell enhancers causes ADM formation, which is consistent
with previous ﬁndings in which the genetic ablation of acinar cell-
related TFs such as Ptf1a, Mist1, and Nr5a2 similarly leads to
ADM in the pancreas47–49. Our results showing that the forced
expression of Ptf1a or Mist1 partially prevents reprogramming-
induced ADM formation further support the conclusion that the
repression of acinar cell enhancers induces ADM formation.
Notably, the transient ADM formation becomes irreversible and
proceeds to PDAC in Kras mutant background, which is
accompanied by continuous activation of the ERK signaling
pathway. The results suggest that transient repression of acinar
cell identity can initiate continuous cancer growth in Kras-
mutated pancreatic cells. Consistently, forced expression of acinar
cell-related TFs (Ptf1a or Mist1) successfully inhibits Kras-
mediated activation of the ERK signaling pathway and ADM
formation in a caerulein-induced pancreatitis model. Given that
ADM is observed in human pancreatitis, a representative risk
factor for PDAC50–52, and pancreatitis promotes PanIN/PDAC
formation in mice53–55, epigenetic ﬂuctuations provoked by
inﬂammatory stimuli may initiate the repression of acinar cell
enhancers, which results in continuous cancer cell growth in
human pancreas. Collectively, we propose that the stable
maintenance of acinar cell enhancers is a roadblock for the cancer
cell growth of Kras-mutated pancreatic cells.
Gradual activation of the ESC regulatory network occurs
during late-stage reprogramming5,6. Here we show that pro-
longed expression of reprogramming factors longer than 1 week
results in the development of different types of cancer in the
pancreas and stomach that is characterized by the expression of
pluripotency-related proteins. Notably, these cancers resemble
human AFP-producing cancer, one of the most fatal adult can-
cers37,38,56, suggesting that epigenetic reorganization related to
late-stage reprogramming may be involved in such cancers.
Consistently, human AFP-producing gastric cancers often co-
express pluripotency-related proteins, such as SALL4, LIN28A,
and LIN28B. Furthermore, these gastric cancers exhibit similar
activation patterns of ESC modules as pluripotent stem cells. Our
results suggest that the activation of pluripotency-related genes
via in vivo reprogramming may be involved in development of
certain types of adult cancers.
In summary, taking advantage of in vivo reprogramming sys-
tems, we show that reprogramming-related epigenetic regulation
has a profound impact on Kras-induced cancer. We propose that
epigenetic ﬂuctuations provoked by environmental factors may
cause a transient dedifferentiation state, which is sufﬁcient for
continuous ERK signaling activation and cancer growth of
quiescent pancreatic cells with Kras mutation.
Methods
Vectors. Pdx1-ires-Cre vector: The cDNA fragment (3.8 kbp) of ires-Cre-pA-PGK-
Puro-pA with 50 bp homologous arms was established using KAPA HiFi Hotstart
Readymix (KAPA Biosystems). This fragment was recombinated into the 3′ side of
the exon 2 of Pdx1 BAC (BACPAC Resources Center) using the Red/ET BAC
recombination system. The fragment of Pdx1-ires-Cre-pA-PGK-Puro-pA sequence
with 3.8 (5′ arm)/2.5 kb (3′ arm) homologous arm was retrieved and used as a
targeting vector. LSL-HA tag-KrasG12D vector: LoxP-PGK-Bsd-pA-LoxP-HA
tag-KrasG12D fragment (1.9 kbp) with 350/750 bp homologous arms was generated
and recombinated into the 5′ side of the untranslated region of the Kras BAC
(BACPAC Resources Center), retrieved with 4.7 (5′ arm)/4.7 kbp (3′ arm)
homologous arm, and used as a targeting vector. Rosa LSL-rtTA3 vector: rtTA3
cDNA construct with Kozak sequence (753 bp) was generated and inserted into
pROSA26-DEST vector (Addgene) using Gateway technology (Thermo Fisher
Scientiﬁc) and used as a targeting vector. pCR8-GW-SNEL vector: A 6.4 kbp
fragment containing Sall4-P2A-Nanog-T2A-Esrrb-E2A-Lin28a cDNA was gener-
ated using In-Fusion HD Cloning Kit (Takara Bio). The cloning primers are shown
in Supplementary Table 3. The Kozak sequence was added to the 5′ side of Sall4
cDNA. This fragment was inserted into pCR8-GW-TOPO using Topo cloning
technology (Invitrogen) and inserted into Col1a1 locus of KH2 ESCs using the ﬂp-
in recombination system24. Rosa::tetO-mCherry vector: mCherry cDNA (717 bp)
was cloned using the primers described in Supplementary Table 3. The Kozak
sequence was added to the 5′ side of mCherry cDNA. This fragment was inserted
into pCR8-GW-TOPO vector using Topo cloning technology (Invitrogen) and
inserted into Rosa::tetO-attR1-ccdB-attR2-ires-mCherry targeting vector as descri-
bed previously57 using Gateway technology. Rosa::tetO-Mist1 vector: Mist1 cDNA
(600 bp) was cloned using the primers described in Supplementary Table 3. The
Kozak sequence was added to the 5′ side of Mist1 cDNA. This fragment was
inserted into pCR8-GW-TOPO using Topo cloning technology (Invitrogen) and
Fig. 5 p53 mutation results in rapid development of in vivo reprogramming-induced PDAC in Kras-mutated pancreas. a A schematic illustration of the
genetic construct of Pdx1 ires-Cre, LSL-KrasG12D, LSL-p53R172H, Rosa LSL-rtTA3, Col1a1::tetO-OSKM-ires-mCherry (KPC-OSKM) mice to induce pancreas-speciﬁc
Kras/p53 compound mutations and in vivo reprogramming. b Experimental protocol for Dox treatment in KPC-OSKM chimeric mice. c Representative
images of the pancreas of C-OSKM, KC-OSKM, KPC-OSKM mice given Dox for 3 days, followed by Dox withdrawal for 1 week. Scale bars, 500 μm. d pERK
and Sirius red staining of the pancreas in KPC-OSKM mice. Scale bars, 100 μm. e Quantiﬁcation of the PDAC area in the pancreas of KC-OSKM and
KPC-OSKM chimeric mice. The PDAC area/affected area is shown. A box-and-whisker plot of the PDAC area/affected area. Solid lines in each box indicate
the median. Bottom and top of the box are lower and upper quartiles, respectively. Whiskers extend to ±1.5 interquartile range (IQR). Numbers in
parentheses indicate the number of mice examined. **p < 0.01, Mann–Whiteney U-test. f A schematic illustration of the genetic construct of KC mouse
with Dox-inducible mCherry, Ptf1a, and Mist1 alleles. g Ptf1a and Mist1 induction inhibit caerulein-induced PanIN formation and activation of ERK signaling,
but mCherry expression does not. Transgenes are induced by Dox treatment starting at 24 h before caerulein treatment. Chimeric mice were sacriﬁced after
7 days of caerulein treatment. Despite the inﬁltration of inﬂammatory cells, PanIN formation and pERK staining are hardly detectable in KC-Ptf1a and KC-
Mist1 chimeric mice. Scale bars, 100 μm. h Quantiﬁcation of the pERK-positive area/mCherry-positive area in the pancreas of caerulein-treated
KC-mCherry, KC-Ptf1a, and KC-Mist1 mice. A box-and-whisker plot of the pERK-positive area/mCherry-positive area. Solid lines in each box indicate the
median. Bottom and top of the box are lower and upper quartiles, respectively. Whiskers extend to ±1.5 interquartile range (IQR). Numbers in parentheses
indicate the number of mice examined. **p < 0.01, *p < 0.05, Mann–Whiteney U-test
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Fig. 6 Prolonged expression of reprogramming factors induces poorly differentiated cancers in KC-OSKM chimeric mice. a Sall4, Lin28a, and Ki67 staining
in undifferentiated pancreatic cancer induced by Dox treatment for 1 week followed by Dox withdrawal for 1 week in KC-OSKM chimeric mice. Scale bar, 50
μm. b Representative macroscopic image, histology, and Ki67 immunostaining of gastric cancer induced by prolonged transient expression of
reprogramming factors in KC-OSKM chimeric mice (Dox On for 2 weeks and then Dox Off for 2 weeks). Scale bars, 100 μm. c Immunotaining for Sall4,
Lin28a, and Afp in poorly differentiated gastric cancers in KC-OSKM chimeric mice. Scale bars, 100 μm. d Incidence of Afp, Sall4, and Lin28a expression in
poorly differentiated gastric cancers in KC-OSKM chimeric mice. e Histology and immunostaining for SALL4, LIN28A, and LIN28B in human AFP-producing
gastric cancers. Scale bar, 100 μm. f Incidence of SALL4-, LIN28A-, and LIN28B-positive cases in human AFP-producing gastric cancers. g Partial activation
of ESC-Core and ESC-Myc modules in human gastric cancers expressing AFP or SALL4
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inserted into Rosa::tetO-attR1-ccdB-attR2-ires-mCherry targeting vector by Gate-
way technology. Rosa::tetO-Ptf1a vector: Ptf1a cDNA was synthesized using a
commercial service (Euroﬁnes genomics). The Kozak sequence was added to the
5′ side of Ptf1a cDNA. The cDNA fragment which was cut by EcoRI and puriﬁed
with Gel/PCR Extraction Kit (Fast Gene), inserted into pCR8-GW-TOPO vector,
and recombinated into Rosa::tetO-attR1-ccdB-attR2-ires-mCherry targeting vector
by Gateway technology. PiggyBac tetO-EGFP-ires-EGFP vector: The EGFP cDNA
(720 bp) and kozac sequence was cloned and inserted into pCR8-GW-TOPO using
Topo cloning technology (Invitrogen) and inserted into PiggyBac tetO- attR1-ccdB-
attR2-ires-EGFP vector (KW509) using Gateway technology. PiggyBac tetO-Ptf1a-
ires-EGFP vector: The Ptf1a cDNA from pCR8-Ptf1a-GW vector described above
was inserted into PiggyBac tetO- attR1-ccdB-attR2-ires-EGFP vector (KW509)
using Gateway technology. PiggyBac tetO-Mist1-ires-EGFP vector: The Mist1
cDNA from pCR8-Ptf1a-GW vector described above was inserted into PiggyBac
tetO- attR1-ccdB-attR2-ires-EGFP vector (KW509) using Gateway technology.
Homologous recombination into ES cells. The ESC lines V6.5 and KH2 were
previously described .24,58 Twenty micrograms of each targeting vector were lin-
earized using speciﬁc restriction enzymes (Pdx1-ires-Cre targeting vector: ScaI,
LSL-HA tag-KrasG12D targeting vector: AsiSI, Rosa LSL-rtTA3 targeting vector:
PvuI, Rosa::tetO-mCherry targeting vector: AsiSI, Rosa::tetO-Mist1 targeting vector:
AsiSI, Rosa::tetO-Ptf1a targeting vector: AsiSI). All restriction enzymes were
obtained from New England Biolabs. After 37 °C overnight linearization, each
product was puriﬁed and collected by ethanol precipitation. The pellets were dis-
solved into 100 μL of 25 mM HEPES buffer (Gibco). ESCs were dissociated with
0.25% trypsin (Nacalai tesque) and dissolved into 500 μL of high glucose DMEM
(Nacalai tesque) containing 25 mM HEPES. A mixture of the targeting vector and
ESCs (4.0 × 106) were injected into Gene Pulser Cuvette (BIO-RAD) and electro-
poration was performed with Gene Pulser Xcell (BIO-RAD). The electroporation
was set at 550 V, 600 ms and performed twice. After electroporation, 2.0 × 106 ESCs
were placed over MEFs in a 6 cm dish (total 2 dishes) and cultured at 37 °C with
5% CO2 in ESC medium (Knockout DMEM (Gibco), 2 mM L-glutamine (Nacalai
tesque), 1× NEAA (Nacalai tesque), 100 U/mL penicillin, and 100 μg/mL strepto-
mycin (Nacalai tesque), 15% fetal bovine serum (Gibco), 0.11 mM mercaptoethanol
(Gibco), and 1000 U/mL human LIF (Wako)). After 24 h of electroporation, we
started the selection with the speciﬁc antibiotics. The concentrations of antibiotics
used in the present study were blasticidinS (Funakoshi) 15 μg/mL, puromycin
(Sigma) 1 μg/mL, G418 (Nacalai tesque) 350 μg/mL, and hygromycin B (Roche)
150 μg/mL. After 1 week of antibiotics selection, the survived ESC colonies were
picked up and expanded to establish ESC lines.
Southern blotting. Genomic DNA was collected from ESCs or pancreatic tissues
using the Purelink Genomic DNA mini Kit (Invitrogen). The recombinated BAC
plasmids were collected using NucleoBond Xtra BAC Kit (Marchery-Nagel). The
extraction was performed according to the manufacturer’s instructions. Three
nanograms of each recombinated BAC as a positive control and 5 μg of sample
genomic DNA were digested with speciﬁc restriction enzymes (Pdx1-ires-Cre: ScaI,
LSL-HA KrasG12D: NheI, LSL-KrasG12D: MfeI, LSL-p53R172H: NheI) at 37 °C over-
night. The restriction enzymes were obtained from New England Biolabs. The
restricted products were ethanol precipitated and then dissolved into 15 μL of TE
buffer. The products were mixed with 5 mL of 6× Loading Buffer Triple Dye
(NIPPON Gene), and electrophoresis was performed in 0.8% agarose gel (Fast
Gene), 50 V for 2 h. The products in the gel were depurinated in 250 mM HCl for
10 min, washed in distilled water for 5 min, and denaturated in 0.5 M NaOH, 1.5 M
NaCl for 15 min two times. The products were then transferred to Hybridization
Transfer Membrane (PerkinElmer) by capillary transfer at room temperature for 8
h. The membrane was washed with 2× Standard Saline Citrate buffer (SSC buffer)
for 5 min twice and crosslinked with CL-1000 Ultraviolet Crosslinker (UVP). The
samples were ﬁxed at pH 7.0 using HCl. The membrane was hybridized at 68 °C
overnight with 25 ng/mL probes in PerfectHyb buffer (TOYOBO). Probes were
generated using the PCR DIG Probe Synthesis Kit (Roche) with wild-type BAC as
the template. The primer sets of each target gene are shown in Supplementary
Table 4. The membrane was washed with low stringency buffer (containing 2× SSC
buffer and 1× SDS) for 5 min twice and high stringency buffer (containing 0.2×
SSC buffer, 1× SDS) for 5 min twice. Next, DIG Luminescent Detection Kit for
Nucleic Acids (Roche) was used for visualization, and LAS4000 (GE Healthcare)
was used for detection.
Blastocyst collection and microinjection. Blastocysts collection: 8-week-old ICR
female mice (Japan SLC) were treated with 7.5 U of serotropin (ASKA Animal
Health) by intraperitoneal injection. After 48 h of serotropin treatment, mice were
injected 7.5 U of gonatropin (ASKA Pharmaceutical). These mice were then mated
with ICR male mice (Japan SLC). Plug check was performed the next morning.
Two days later, these female mice were sacriﬁced by cervical dislocation and
operated to pick out oviducts. Two-cell stage fertilized eggs were collected by
perfusion with M2 medium (Sigma) and maintained in KSOM medium. Two days
later, the obtained blastocysts were used for microinjection. For microinjection,
ESCs were treated with trypsin and pipetted 15 times to dissociate them into single
cells. The single cells were cultured in a gelatin-coated 10-cm dish with 10 mL ESC
medium for 30 min to attach MEFs onto the dish. Three milliliters of supernatant
containing ESCs was collected. Three to ﬁve ESCs were injected into the ICR
blastocysts under an OLYMPUS IX71 microscope. Twenty to 25 injected blas-
tocysts were transplanted into the uterus of pseudopregnant ICR female mice
(Japan SLC).
Establishment of ESCs. Collected blastocysts were placed on the MEFs in a
24-well dish and cultured with 500 μL of 2i-containing ESC medium (1 μM of
PD0325901 (STEMGENT) and 3 μM of CHIR99021 (STEMGENT) in ESC
medium)59. One hundred microliters of 2i-ESC medium was added into each well
every day. One week later, the colonies were passaged and expanded in ESC
medium on the MEFs. Male ESCs were selected by genotyping Sry allele using Go
taq Master Mix (Promega). Genotyping primers are described in Supplementary
Table 5.
Mice. Rosa LSL-LacZ mice16, LSL-KrasG12D mice18, LSL-p53R172H mice19, and
Col1a1::tetO-OSKM-ires-mCherry mice8,60 have been described previously. All
mice were maintained on a C57BL/6 and 129X1/Sv mixed background. For
germline transmission, 8-week-old male chimeric mice were mated with 8-week-
old C57BL/6 female mice (Japan SLC) to obtain transgenic mice. All chimeric mice
were generated by injecting male ES cells which have C57BL/6 and 129X1/Sv
mixed genetic background into blastocysts of ICR mice.
Mice experiment. All animal studies were conducted in compliance with ethical
regulations in Kyoto University and were approved by Center for iPS Cell Research
and Application (CiRA), Kyoto University. To obtain the unbiased and reliable
results, more than ﬁve mice were used in each group. Sample size was indicated in
each ﬁgure. A few mice had been excluded because of the mortality before the
evaluation. The coat color chimerism of chimeric mice was evaluated before
experiments (Supplementary Fig. 5B). Mice that had no chimeric contribution had
been excluded in each experiment.
Mice genotyping. Ear tips of 3-week-old mice were collected and dissolved in 500
μL of DNA elution buffer (containing 100 mM Tris HCl, 5 mM EDTA, 0.2% SDS,
200 mM NaCl, and 1% Protein kinase) at 65 °C. After centrifugation at 4 °C and
15,000 rpm for 5 min, 300 μL of supernatant was collected and mixed with
equivalent isopropyl alcohol and vortexed. After centrifugation at 4 °C and 15,000
rpm for 10 min, the pellet was mixed with 70% of ethanol and precipitated. Then
the pellet was dissolved in 50 μL of Tris-EDTA buffer. Recombination was detected
by PCR with Go taq Master Mix and Polymerase (Promega). Genotyping Primers
are shown in Supplementary Table 5.
Alkaline phosphatase staining of Dox-treated KH2-SNEL MEFs. MEFs from
E13.5 of KH2-SNEL chimeric mice were cultured with 2.0 μg/mL of Dox in ESC
medium for 2 weeks. ALP staining was performed according to the manufacturer’s
instructions using the ALP stain Kit (Muto Pure Chemicals).
X-gal staining. The precise procedure was described previously61. Whole mount
staining: Mice under anesthesia were perfused through the vascular system with 10
mL of phosphate-buffered saline (PBS) to clear the blood. Perfusion was performed
with 10 mL of 4% PFA to obtain adequate ﬁxation. The dissected pancreas of Pdx1-
ires-Cre, Rosa LSL-LacZ mice were collected and ﬁxed with
ice-cold 4% PFA for 1 h. The tissues were poured into PBS containing 10% of
sucrose, and then into PBS containing 20% of sucrose (Nacalai Tesque) for 1 h,
respectively, and then placed in PBS containing 30% of sucrose at 4 °C for over-
night. Next the pancreas was poured into permeabilization solution (5 mM EGTA,
2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% Nonidet P-40 in PBS) and
reacted with the X-gal solution (1 mg/mL X-gal, 5 mM potassium ferrocyanide, and
5 mM potassium ferricyanide in the permeabilization solution) at 37 °C for 6 h.
Frozen tissue staining: After ﬁxation of the dissected tissues with PBS containing
30% sucrose, the pancreas was embedded in Tissue-Tek O.C.T compound
(Sakura). Frozen tissues were cut serially into 10-μm-thick sections and stained
with the procedure described above. Counterstaining was performed using Nuclear
Fast Red (Merck Millipore).
Doxycycline treatment. Doxycycline (Sigma) was dissolved in drinking water at 2
mg/mL. For quantitative PCR (qPCR) and ChIP-seq of the pancreas of C-OSKM
mice, Dox-containing PBS was intraperitoneally injected to induce uniform
transgene expressions (1 mg/injection every consecutive 12 h until sacriﬁce). To
maintain acinar cell enhancer in Ptf1a or Mist1-inducible mice, we started Dox
administration to induce Ptf1a or Mist1 24 h before caerulein treatment.
Caerulein treatment. The precise procedure was described previously28. We
performed intraperitoneal injection of caerulein (Sigma) eight times for 2 days
(2 μg/injection every consecutive hour for 7 h). Caerulein was dissolved in PBS.
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RNA extraction from tissues. The tissues of mice were freshly collected and
dipped into 1 mL of RNA later (Invitrogen) overnight at 4 °C. Subsequently, the
tissues were poured into 1 mL of Sepazol (Nacalai tesque) and shattered with a
sonicator (Qsonica) for 5 s. After centrifugation at 4 °C and 12,000 g for 10 min,
supernatants were carefully collected and mixed with 200 μL of chloroform
(Wako). After shaking for 15 s, the mixtures were left to stand for 2 min at room
temperature and centrifuged at 4 °C and 12,000 g for 15 min. Three hundred
microliters of supernatant was carefully collected and mixed with 300 μL of 70%
ethanol. The mixtures were injected into RNeasy spin column (Qiagen), and RNA
was extracted according to the manufacturer’s instructions.
Quantitative RT-PCR. RNA was extracted using RNeasy Plus Mini Kit (Qiagen)
according to the manufacturer’s protocol. RNA was quantiﬁed with NanoDrop
(Thermo Scientiﬁc). Five-hundred nanograms of RNA was used for the reverse
transcription reaction into cDNA by using PrimeScript RT reagent Kit (Takara
Bio). Real-time qPCR was performed by using Go Taq qPCR Master Mix (Pro-
mega). Transcript levels were normalized by β-actin. The PCR primers are shown
in Supplementary Table 6.
Western blotting from the pancreatic tissue. The pancreatic tissues were sec-
tioned into 5 × 5mm and shattered with a sonicator (Qsonica) for 5 s in RIPA
buffer (10 mM of Tris HCl (pH 8.0), 150 mM HCl, 1% Triton, 1% DOC, and
0.1% SDS) containing 0.5% Protease inhibitor, 1% DTT and 100× phosphatase
inhibitor (Nacalai tesque) on ice. After centrifugation at 20,000 g for 10 min, the
100 μL of supernatants were collected. The quantity was determined with a
Molecular Devices VersaMax Microplate Reader (Marshall Scientiﬁc) using Quick
start protein assay Kit (BIO-RAD). The samples were processed in 30 μg, and
denatured at 95 °C for 5 min. Electrophoresis was performed in 10% SDS-PAGE
gel, 100 for 15 and 200 V for 35 min with the use of PowerPac HC (BIO-RAD).
Next, the protein in the gel was transferred onto the Amersham Hybond-P PVDF
Membrane (GE HealthCare). Membranes were blocked for 60 min with 4% Skim
Milk (Nacalai Tesque) in 1× TBS with 0.05% Tween-20 (TBST) and then incubated
with primary antibodies in blocking buffer (4% Skim Milk in TBST) overnight at 4
°C. The lists of antibodies and dilutions are shown in Supplementary Table 7. The
membrane was washed in TBST and incubated with secondary antibodies in
blocking buffer for 1 h at room temperature. The membrane was washed in TBST
again, then incubated with Pierce ECL plus Western Blotting Substrate (Thermo
Scientiﬁc) for visualization. The bands were detected with LAS4000 (GE
HealthCare).
Parafﬁn-embedded specimen preparation. The dissected tissue samples were
ﬁxed in 4% PFA (Wako) for overnight at room temperature. The next day, the
samples were poured into 70% ethanol (Wako) for several hours, and then poured
into 80% ethanol, 90% ethanol, 100% ethanol, and xylene (Wako), and embedded
in parafﬁn using a spin tissue processor (STP120; Thermo Scientiﬁc). Sections were
sliced into 3–4 μm thickness, and stained with hematoxylin and eosin (Muto Pure
Chemicals). Serial sections were used for the immunohistochemical analyses.
Immunostaining. The samples were soaked in xylene for 5 min three times to
remove parafﬁn and 100% ethanol for 5 min three times to hydrophilize. After
washing with water for several min, the samples were soaked in epitope retrieval
buffer (Nichirei Bioscience) and microwaved at 100W for 10 min. The samples
were then soaked in 1× PBS for several min, and incubated with 150 μL primary
antibodies in PBS with 2% bovine serum albumin (BSA) (MP Biomedicals) for 1 h
at room temperature. The lists of antibodies and dilutions are shown in Supple-
mentary Table 7. After washing with PBS for 5 min two times, the samples were
processed with secondary antibodies for 30 min at room temperature. The samples
were washed in PBS for 5 min two times, and nuclear staining was performed with
hematoxylin for 10–30 s. After washing with water for 10 min, the samples were
poured into 100% ethanol three times and placed in xylene three times. The
samples were evaluated under a microscope (Olympus BX41).
Immunoﬂuorescent staining. The same procedure as immunostaining described
above was performed until primary antibodies treatment. The samples were pro-
cessed with 500× DAPI (Invitrogen) and 150× ﬂuorescence-labeled secondary
antibodies diluted with 0.5% BSA PBS, for 90 min at room temperature. The lists of
antibodies and dilutions are shown in Supplementary Table 7. After washing in
PBS for 5 min two times, the samples were mounted and evaluated with a confocal
laser scanning microscope (Zeiss LSM700).
Alcian blue staining. Tissue samples were soaked into xylene for 5 min three
times, 100% ethanol for 5 min three times, washed with water for several minutes,
and ﬁnally stained with Alcian blue 8GX solution (Merck Millipore) and nuclear
fast red (Merck Millipore), according to the manufacturer’s protocol.
Sirius red staining. Tissue samples were soaked in xylene for 5 min three times
and 100% ethanol for 5 min three times, washed with water for several minutes,
and stained with Picro-Sirius Red Stain Kit (PSI).
Microarray analysis. Two hundred nanograms of total RNA prepared from the
pancreatic tissues was subjected to cDNA synthesis with a WT Expression Kit
(Ambion), and the resultant cDNA was fragmented and hybridized to a Mouse
Gene 1.0 ST Array (Affymetrix). After hybridization, GeneChip arrays were
washed and stained using GeneChip Fluidics Station 450 (Affymetrix) and detected
with the Scanner 3000 TG system (Affymetrix) following the manufacturer’s
standard protocols. The data were analyzed using GeneSpring GX software (ver-
sion 14.8; Agilent Technologies).
Chromatin immunoprecipitation from pancreatic tissue. Perfusion ﬁxation with
ice-cold 4% PFA (Wako) was employed for ﬁxation of the pancreatic tissue of C-
OSKM mice. The pancreas was dissected after 5 min of ﬁxation and treated with
glycine to quench the formaldehyde. ChIP was performed as described pre-
viously62. H3K27Ac antibody (Monoclonal Antibody Lab) was used for the ChIP
analysis, and mouse IgG antibody (Abcam) was used as a control.
ChIP-seq. Puriﬁed ChIP DNA (5 ng per sample) was used for the generation of
sequencing libraries with TruSeq ChIP Sample Prep Kit (Illumina). The resultant
DNA libraries were assessed on Agilent Bioanalyzer and quantiﬁed with KAPA
Library Quantiﬁcation Kits (KAPA BIOSYSTEMS). The libraries were sequenced
to generate single-end 86 bp reads using NextSeq 500 (illumina).
ChIP-seq data analysis. ChIP-Seq Peak calls were made as previously described63.
Brieﬂy, the low-quality bases at the 3′ read ends and the adaptors were trimmed
using cutadapt-1.9.1 (ref. 63). Untrimmed and trimmed reads of 20 bp or longer
were mapped to mouse genome (mm10) with BWA 0.7.12 (ref. 64). Duplicate reads
and low mapping quality reads (MAPQ < 20) were removed using Picard (http://
broadinstitute.github.io/picard/) and SAMtools65 for further analysis. Mapped
reads were visualized using igv-2.3 (ref. 66). Peaks were called using MACS2 (ref.
67) plus IDR framework developed by the ENCODE project68. The reads mapped
to the blacklisted regions (https://sites.google.com/site/anshulkundaje/projects/
blacklists) and sex chromosomes were excluded for the peak calling. The heatmaps
for ChIP-Seq data were drawn using the ngsplot-2.47 program69. Super enhancers
were identiﬁed by H3K27ac with ROSE pipelines29,30. Super enhancers identiﬁed
in this study were assigned to the transcripts whose TSS were within the SEs.
Bisulﬁte sequencing from pancreatic tissue. Freshly collected pancreatic tissues
were frozen in liquid nitrogen and grounded into powder using mortar. Genome
DNA of the pancreas was extracted using Purelink Kit (Invitrogen) according to
the manufacturer’s protocol. Bisulﬁte treatment was performed using EZ DNA
Methylation-Gold Kit (Zymo Research). The target sequence was cloned by Ex Taq
HS (Takara Bio) and ligated into pCR4-Topo vector using Topo cloning tech-
nology (Invitrogen). These plasmids were transformed into DH5α at 37 °C, over-
night. Colony PCR was performed using Go taq Master Mix (Promega) and
ascertained ligation of the cassettes. After cleanup of the PCR products by exo-
nuclease I (New England Biolabs) and shrimp alkaline phosphatase (Takara Bio),
the sequence reaction was performed using M13 Rv primer (5′-CAGGAAA-
CAGCTATGAC-3′) and was sequenced with ABI 3500 xL (Applied Biosystems).
Methylation rates were measured using Quantiﬁcation tool for Methylation Ana-
lysis (QUMA) software (Riken).
Quantiﬁcation analysis. To quantify the immunostained tissue samples, immu-
nostained section was randomly photographed at ×200 magniﬁcation three times
for each mouse. The pictures were processed with ImageJ software (NIH) to
evaluate the positive area of each CK19, phospho-ERK, Alcian blue, Sirius red, and
EGFR staining. The positive area was determined as the mean of positive area in
three independent histological images. The results were evaluated with Graphpad
Prism 7 software for quantiﬁcation. To assess γH2AX-, p21-, Ki67-, Caspase
3-positive rates, we randomly photographed epithelial area of the pancreas at ×200
magniﬁcation. The positive nucleus of epithelial cells was counted. The number of
each positive nucleus was divided by the number of total nucleus of epithelial cells.
For quantiﬁcation of immunoﬂuorescent samples, section was randomly photo-
graphed at ×200 magniﬁcation. The ratio of CK19-positive cells in
EGFP-expressing cells was determined in ten independent immunoﬂuorescent
images for each cohort.
Statistical analysis of tissue samples. Statistical parameters including statistical
signiﬁcance and n values are described in the ﬁgures. Statistical analyses were
carried out using Prism 7 Software (GraphPad). For statistical comparison of two
groups, we performed Mann–Whiteney U-test (two-tailed, 95% conﬁdence inter-
vals). A box-and-whisker plot is used to display information about the range, the
median and the quartiles. Solid lines in each box indicate the median. Bottom and
top of the box are lower and upper quartiles, respectively. Whiskers extend to ±1.5
interquartile range (IQR). Numbers in parentheses indicate the number of mice
examined. *p < 0.05, **p < 0.01, ***p < 0.001. n.s., not signiﬁcant.
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Patients-derived parafﬁn-embedded tissue samples. Human patients-derived
parafﬁn-embedded tissue samples were used in compliance with ethical regulations
in Kyoto University Hospital.
Statistical analysis of survival. Kaplan–Meier survival curves were calculated
using the survival time for each mouse. The Log-rank test was used to test for
signiﬁcant differences between the groups using Prism 7 Software (GraphPad).
Data availability. ChIP-seq and microarray data reported in this study have been
deposited to the Gene Expression Omnibus (GEO) under accession GSE100842.
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